<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    Biodesix to Report Third Quarter 2022 Financial Results on Nov. 3, 2022

    Biodesix will release financial results for the third quarter before the open of trading on November 3. Biodesix’s will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. ET.

    Biodesix to Present Data at the CHEST 2022 Annual Meeting

    Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs

    Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference

    Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.

    Biodesix Announces Third Quarter 2022 Results and Highlights

    Third quarter 2022 core Lung Diagnostic revenue of $9.2 million increased 102% over the comparable period in 2021; U.S. Federal Supply Schedule Contract expands coverage to Veterans Health Administration and Military Health System Medical Centers for its entire Lung Diagnostic portfolio.

    Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions

    Biodesix Expands Coverage to Veterans Health Administration and Military Health System Medical Centers for Its Entire Lung Diagnostic Portfolio

    Biodesix Announces Preliminary Revenue for Third Quarter 2022

    Biodesix expects to report third quarter 2022 total revenue to be in the range of $10.6 million to $11.2 million, representing growth of 62% to 71% over the third quarter 202, reflecting continued growth in the Company’s core lung diagnostic testing.

    Biodesix to Participate in Two Upcoming Investor Conferences in September

    Biodesix to participate at Morgan Stanley 20th Annual Global Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference

    Biodesix Announces Second Quarter 2022 Results and Highlights

    Biodesix, Inc. (Nasdaq: BDSX) announced its financial and operating results for second quarter ended June 30, 2022 and provided a corporate update.

    Canaccord Genuity 42nd Annual Growth Conference

    Rewatch the live fireside chat during Canaccord Genuity 42nd Annual Growth Conference, featuring Scott Hutton, CEO of Biodesix Inc.

    Biodesix Named a Top 100 Healthcare Technology Company of 2022

    Biodesix is recognized in the Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022.

    1 2 3 4 5 6 7 8 9